UNICHEMLABBSEUnichem Laboratories LtdMediumNeutral
Announced Fri, 22 May · 16:58 IST

Audited Financial Results for the year ended 31st March 2026

Promoter Family Board EntryManagement Changes View source PDF

UNICHEMLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-4.7%1-day move
₹372.60
prior close
₹361.05
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.4-0.9-1.0-0.8-4.7-5.2-6.1-8.9-1.8-0.9+19.8+16.1+45.0
Up moveDown movePending
AI summary

Unichem Laboratories reported strong full-year results with consolidated revenue from operations of ₹2,201.85 crore, up 4.3% from ₹2,110.97 crore in the previous year. Profit after tax surged 84% to ₹252.84 crore from ₹137.52 crore, driven by a ₹275.52 crore gain from sale of the erstwhile registered office land and building. EPS improved to ₹35.91 per share from ₹19.53. The company also settled a European Commission fine of Euro 19.55 million in October 2025 and recognised ₹15.40 crore impact from new Indian labour codes. Mr. Pabitrakumar Bhattacharyya was redesignated as Managing Director & CEO and reappointed for three years from August 2026. The Irish subsidiary was sold to Ipca Laboratories in April 2025.

Likely market impact

The company delivered robust profitability growth on the back of one-time asset gains and improved operational performance. The CEO consolidation and auditor reappointments signal stable governance. The strong cash position of ₹289 crore provides flexibility for growth investments.